Elicio Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $2.3M | $28.3M |
| Cost of revenue | — | — | — | $0 | $433,000 |
| Research and development | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M |
| Interest expense | $1.1M | $455,000 | $1.1M | $3.6M | — |
| Pretax income | -$39.6M | -$51.9M | — | -$38.8M | -$54.6M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M |
| Balance Sheet | |||||
| Cash and equivalents | $18.6M | $17.6M | $12.9M | $6.2M | $88.8M |
| Current assets | $19.3M | $20.7M | $16.3M | $10.7M | $91.2M |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M |
| Current liabilities | $8.1M | $11.5M | $9.8M | $6.9M | $11.3M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M |
| Stockholders' equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M |
| Depreciation and amortization | $204,000 | $321,000 | $382,000 | $390,000 | $91,000 |
| Stock-based compensation | $2.7M | $1.5M | $1.2M | $579,000 | $12.0M |
| Capital expenditure | $16,000 | $87,000 | $66,000 | $654,000 | $382,000 |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M |
| Share repurchases | — | $0 | $150,000 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 19.1M · Free float 33.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.